PGL prospa group limited.

time to short it hard

  1. 498 Posts.
    Should retreat below $3 in the coming weeks. Nexavar is much more than just serious competition, and PI-88 does not have anything close to the efficacy that Nexavar has demonstrated as the best-in-class treatment regime.

    The sp may well go into freefall, as the viability of their drug development program is brought into question.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.